AMRN Amarin Corporation plc - American Depositary Shares
$13,99
السعر · أغسطس 18, 2026
البيانات الأساسية اعتبارًا من يوليو 29, 2026
نطاق 52 أسبوعًا
$13–$21
13% of range
تقييم المحللين
HOLD
6 analysts
السعر المستهدف
$12
P/E (TTM)
-155.4
ROE
-8.4%
هامش صافي الربح
-18.2%
حول Amarin Corporation plc - American Depositary Shares نظرة عامة على الشركة من ويكيبيديا
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.
اقرأ المزيد
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.
In July 2012, their lead-candidate drug named Vascepa (AMR-101) received FDA-approval, competing against GlaxoSmithKline's Lovaza.
History
Amarin Corporation plc (formerly Ethical Holdings plc) was originally incorporated in England as a private limited company on March 1, 1989, and later re-registered as a public company on March 19, 1993. In 2002, the company suffered losses worth $37 million; 2003 losses exceeded $19 million. As of 2005, it was developing neurology drugs. It developed Miraxion to treat serious hereditary neurodegenerative disease.
In December 2007, Amarin acquired Ester Neurosciences Limited for US$8.1 million. In 2011, CEO Joe Zakrzewski said that the company would like to first work on building its infrastructure out to commercialize the drug in the United States.
Products and development
Vascepa (USA) / Vazkepa (EU)
Amarin´s sole product VASCEPA® came on the market in 2013 for triglyceride levels >=500 milligrams per deciliter. In December 2019, the FDA approved "...the use of Vascepa (icosapent ethyl) as an adjunctive (secondary) therapy to reduce the risk of cardiovascular events among adults with elevated triglyceride levels (a type of fat in the blood) of 150 milligrams per deciliter or higher. Patients must also have either established cardiovascular disease or diabetes and two or more additional risk factors for cardiovascular disease....Vascepa is the first FDA approved drug to reduce cardiovascular risk among patients with elevated triglyceride levels as an add-on to maximally tolerated statin therapy.
Furthermore, VASCEPA® is in use in clinical trials by 3rd parties to see, if it has an effect on Alzheimer, Colon Cancer, Nonalcoholic Steatohepatitis (NASH), and other diseases.
HLS Therapeutics, Amarin´s license partner in Canada, presented results of their COVID-19 clinical trial for Vascepa at National Lipid Association Scientific Sessions 2020, December 12. The results demonstrated a 25% reduction of hs-CRP, a biomarker for inflammation. Most people with COVID-19 die, because of a cytokine storm, which causes an uncontrolled and excessive release of pro-inflammatory signaling molecules called cytokines. Two more COVID-19 studies are actually running with Vascepa to validate and proof further benefits.
On January 28, the Committee for Medicinal Products for Human Use gave a positive recommendation for Vazcepa (its name in the EU), which the European Commission finally approved on March 30.
Patent disputes
On March 30, 2020, the designated patent judge in the U.S. District Court for the District of Nevada, Miranda Du, ruled for generic-drug makers Hikma Pharmaceuticals and Dr. Reddy's Laboratories in a lawsuit with Amarin over patents on Amarin's drug, Vascepa. Soon after, on April 2, 2020, Amarin filed an appeal of the ruling. The appeal was lost and an en-banc was also not granted, afterwards. On November 30, three weeks after Hikma Pharmaceuticals started the distribution of their generic version of Vascepa, Amarin filed a complaint of patent infringement against Hikma. On February 11, 2021, Amarin filed a petition for certiorari with the US Supreme Court. On June 21, 2021, the petition was denied.
== Finance ==
المصدر: ويكيبيديا (الإنجليزية), CC BY-SA 4.0 · عرض على ويكيبيديا ↗
AMRN لقطة سريعة للسهم السعر، القيمة السوقية، مكرر الربحية (P/E)، ربحية السهم (EPS)، العائد على حقوق الملكية (ROE)، نسبة الدين إلى حقوق الملكية، نطاق 52 أسبوعًا
السعر
$13.99
القيمة السوقية
$5.82B
P/E (TTM)
-155.4
ربح السهم (آخر 12 شهرًا)
$-0.09
الإيرادات (آخر 12 شهرًا)
$214M
عائد التوزيعات
—
ROE
-8.4%
D/E الدين/حقوق الملكية
—
نطاق 52 أسبوعًا
$13 – $21
AMRN مخطط سعر السهم OHLCV يومي مع مؤشرات فنية — تحريك وتكبير وتخصيص عرضك
Configure
أداء 10 سنوات اتجاهات الإيرادات وصافي الدخل والهوامش وربحية السهم
الإيرادات وصافي الدخل
$214M
2016-12-31
→
2025-12-31
ربح السهم
$-0.09
2016-12-31
→
2025-12-31
التدفق النقدي الحر
—
2016-12-31
→
2020-12-31
الهوامش
-18.2%
2016-12-31
→
2025-12-31
التقييم نسب مكرر الربحية (P/E)، مكرر المبيعات (P/S)، مكرر القيمة الدفترية (P/B)، EV/EBITDA — هل السهم مرتفع السعر أم رخيص؟
المقياس
اتجاه 5 سنوات
AMRN
متوسط الأقران
P/E (TTM)
-155.4
55.9
P/S (TTM) (السعر / المبيعات (آخر 12 شهرًا))
27.3
5.5
P/B (السعر / القيمة الدفترية)
12.7
1.8
الربحية هامش الربح الإجمالي والتشغيلي والصافي؛ العائد على حقوق الملكية (ROE)، العائد على الأصول (ROA)، العائد على رأس المال المستثمر (ROIC)
المقياس
اتجاه 5 سنوات
AMRN
متوسط الأقران
Gross Margin (هامش الربح الإجمالي)
56.6%
63.8%
Operating Margin (هامش التشغيل)
-23.5%
—
Net Profit Margin (هامش صافي الربح)
-18.2%
-14.2%
ROA (العائد على الأصول)
-5.7%
-4.2%
ROE
-8.4%
-6.0%
ROIC
-11.8%
—
الصحة المالية الديون، السيولة، الملاءة المالية — قوة الميزانية العمومية
المقياس
اتجاه 5 سنوات
AMRN
متوسط الأقران
Current Ratio (النسبة الحالية)
3.3
3.7
Quick Ratio (النسبة السريعة)
2.2
—
النمو نمو الإيرادات وربحية السهم وصافي الدخل: مقارنة بالعام السابق (YoY)، متوسط النمو السنوي المركب لـ 3 سنوات (3Y CAGR)، متوسط النمو السنوي المركب لـ 5 سنوات (5Y CAGR)
المقياس
اتجاه 5 سنوات
AMRN
متوسط الأقران
Revenue YoY (الإيرادات مقارنة بالعام السابق)
-6.6%
—
Revenue CAGR 3Y (معدل نمو الإيرادات السنوي المركب لـ 3 سنوات)
-16.7%
—
Revenue CAGR 5Y (معدل نمو الإيرادات السنوي المركب لـ 5 سنوات)
-19.0%
—
كفاءة رأس المال معدل دوران الأصول، معدل دوران المخزون، معدل دوران المستحقات
المقياس
اتجاه 5 سنوات
AMRN
متوسط الأقران
AMRN توافق الآراء التحليلي آراء المحللين الصعودية والهبوطية، السعر المستهدف لمدة 12 شهرًا، الصعود
بيع
6 محللين
- شراء قوي 0 0,0%
- شراء 0 0,0%
- احتفاظ 2 33,3%
- بيع 2 33,3%
- بيع قوي 2 33,3%
السعر المستهدف لمدة 12 شهرًا
1 محللين · 2026-08-15
منخفض
$12.00
مرتفع
$12.00
السعر المستهدف الوسيط
$12.00
-14,2%
السعر المستهدف المتوسط
$12.00
-14,2%
سجل الأرباح ربحية السهم الفعلية مقابل التقديرات، نسبة المفاجأة %، معدل التجاوز، تاريخ الأرباح التالي
متوسط المفاجأة
0.20%
| الفترة | EPS Actual | EPS المتوقع | المفاجأة |
|---|---|---|---|
| 30 يونيو، 2026 | $0.04 | $-0.01 | 0.05% |
| 31 مارس، 2026 | $-0.09 | $0.09 | -0.18% |
| 31 ديسمبر، 2025 | $0.01 | $0.00 | 0.01% |
| 30 سبتمبر، 2025 | $0.08 | $-0.58 | 0.66% |
| 30 يونيو، 2025 | $0.66 | $-0.18 | 0.84% |
| 31 مارس، 2025 | $-0.76 | $-0.58 | -0.18% |
مقارنة الأقران (الصناعة الفرعية GICS) المقاييس الرئيسية مقابل أقران القطاع
| الرمز | القيمة السوقية | P/E | الإيرادات سنويًا | هامش الربح الصافي | ROE | هامش الربح الإجمالي |
|---|---|---|---|---|---|---|
| AMRN | $5.81B | -155.1 | -6.6% | -18.2% | -8.4% | 56.6% |
| ALKS | $4.63B | 19.6 | -5.2% | 16.4% | 14.0% | — |
| PRTA | $514M | -2.1 | -92.8% | -2520.6% | -63.6% | — |
الأساسيات الكاملة جميع المقاييس حسب السنة — قائمة الدخل، الميزانية العمومية، التدفق النقدي
قائمة الدخل 18
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $214M | $229M | $307M | $369M | $583M | $614M | $430M | $229M | $181M | $130M | $82M | $54M | |
| Cost of Revenue | · | · | · | · | $121M | $131M | $96M | $55M | $45M | $34M | $28M | $20M | |
| Gross Profit | $121M | $81M | $166M | $242M | $462M | $483M | $334M | $175M | $136M | $96M | $54M | $34M | |
| R&D Expense | $20M | $21M | $22M | $30M | $29M | $39M | $34M | $56M | $47M | $50M | $51M | $50M | |
| SG&A Expense | $115M | $152M | $200M | $304M | $408M | $463M | $324M | $227M | $135M | $111M | $101M | $79M | |
| Operating Expenses | $171M | $173M | $233M | $348M | $451M | $502M | $358M | $283M | $182M | $161M | $152M | $130M | |
| Operating Income | $-50M | $-92M | $-68M | $-106M | $11M | $-20M | $-24M | $-108M | $-46M | $-66M | $-98M | $-96M | |
| Interest Expense | $7.0K | $7.0K | $8.0K | $15.0K | $129.0K | $3M | $7M | $9M | $10M | $19M | $20M | $19M | |
| Interest Income | $11M | $13M | $12M | $3M | $1M | $5M | $8M | $1M | $429.0K | $234.0K | $132.0K | $96.0K | |
| Other Non-op | $3M | $1M | $2M | $-740.0K | $-302.0K | $104.0K | $-75.0K | $-326.0K | $74.0K | $-482.0K | $-228.0K | $4M | |
| Pretax Income | $-36M | $-77M | $-54M | $-104M | $11M | $-17M | $-22M | $-116M | $-55M | $-76M | $-118M | $-59M | |
| Income Tax | $3M | $5M | $5M | $2M | $4M | $745.0K | $164.0K | $96.0K | $13M | $10M | $-3M | $-3M | |
| Net Income | $-39M | $-82M | $-59M | $-106M | $8M | $-18M | $-23M | $-116M | $-68M | $-86M | $-115M | $-56M | |
| EPS (Basic) | $-0.09 | $-0.20 | $-0.15 | $-0.26 | $0.02 | $-0.05 | $-0.07 | $-0.39 | $-0.25 | $-0.41 | $-0.83 | $-0.32 | |
| EPS (Diluted) | $-0.09 | $-0.20 | $-0.15 | $-0.26 | $0.02 | $-0.05 | $-0.07 | $-0.39 | $-0.25 | $-0.41 | $-0.83 | $-0.36 | |
| Shares (Basic) | 414,984,000 | 410,937,000 | 407,655,000 | 401,155,000 | 395,992,000 | 381,759,000 | 342,538,000 | 297,237,000 | 270,652,000 | 211,874,000 | 180,654,000 | 173,719,000 | |
| Shares (Diluted) | 414,984,000 | 410,937,000 | 407,655,000 | 401,155,000 | 402,480,000 | 381,759,000 | 342,538,000 | 297,237,000 | 270,652,000 | 211,874,000 | 180,654,000 | 173,824,000 | |
| EBITDA | $-50M | $-92M | $-68M | · | · | $-20M | · | $-108M | $-46M | $-66M | $-98M | $-96M |
الميزانية العمومية 27
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $135M | $121M | $199M | $218M | $219M | $187M | $645M | $249M | $74M | $98M | $107M | $120M | |
| Short-term Investments | $168M | $173M | $121M | $92M | $235M | $314M | · | · | · | · | · | · | |
| Receivables | $127M | $122M | $134M | $131M | $164M | $155M | $116M | $67M | $45M | $20M | $14M | $8M | |
| Inventory | $196M | $166M | $259M | $229M | $235M | $189M | $77M | $58M | $30M | $21M | $19M | $14M | |
| Prepaid Expense | $24M | $13M | $12M | $19M | $22M | $31M | $13M | $3M | $3M | $7M | $3M | $3M | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | · | · | $3M | |
| Current Assets | $650M | $595M | $725M | $689M | $879M | $879M | $855M | $378M | $153M | $146M | $144M | $145M | |
| PP&E (Net) | $12.0K | $16.0K | $114.0K | $874.0K | $1M | $2M | $2M | $63.0K | $28.0K | $78.0K | $243.0K | $381.0K | |
| PP&E (Gross) | $1M | $1M | $1M | $3M | $3M | $4M | $3M | $902.0K | $844.0K | $821.0K | $997.0K | $969.0K | |
| Accum. Depreciation | $1M | $1M | $1M | $2M | $2M | $2M | $1M | $839.0K | $816.0K | $755.0K | $754.0K | $588.0K | |
| Intangibles | $13M | $16M | $19M | $22M | $24M | $14M | $15M | $7M | $8M | $9M | $9M | $10M | |
| Other Non-current Assets | $1M | $1M | $1M | $458.0K | $456.0K | $432.0K | $1M | $174.0K | $174.0K | $741.0K | $174.0K | $3M | |
| Total Assets | $671M | $685M | $832M | $886M | $1.07B | $966M | $882M | $386M | $162M | $167M | $173M | $171M | |
| Accounts Payable | $45M | $40M | $53M | $65M | $115M | $106M | $50M | $38M | $25M | $6M | $11M | $9M | |
| Current Liabilities | $194M | $180M | $259M | $259M | $371M | $307M | $242M | $157M | $109M | $76M | $51M | $40M | |
| Capital Leases | $6M | $8M | $9M | $10M | $9M | $9M | $9M | · | · | · | · | · | |
| Other Non-current Liabilities | $11M | $12M | $9M | $8M | $8M | $6M | $4M | $11M | $1M | $710.0K | $335.0K | $386.0K | |
| Total Liabilities | $211M | $199M | $280M | $291M | $401M | $339M | $274M | $233M | $227M | $176M | $301M | $260M | |
| Long-term Debt | · | · | · | · | · | · | $50M | $80M | $92M | $94M | $92M | $105M | |
| Total Debt | · | · | · | · | · | $0 | · | $80M | $93M | $101M | $106M | $105M | |
| Common Stock | $310M | $305M | $303M | $299M | $294M | $290M | $269M | $247M | $209M | $207M | $150M | $143M | |
| Paid-in Capital | $1.92B | $1.91B | $1.90B | $1.89B | $1.86B | $1.82B | $1.76B | $1.28B | $978M | · | · | · | |
| Retained Earnings | $-1.71B | $-1.67B | $-1.59B | $-1.53B | $-1.42B | $-1.43B | $-1.41B | $-1.39B | $-1.27B | $-1.20B | $-1.12B | $-970M | |
| Treasury Stock | $67M | $65M | $64M | $62M | $61M | $51M | $36M | $10M | $4M | $1M | $411.0K | $217.0K | |
| Stockholders' Equity | $459M | $486M | $552M | $595M | $667M | $628M | $608M | $152M | $-65M | $-9M | $-129M | $-88M | |
| Liabilities + Equity | $671M | $685M | $832M | $886M | $1.07B | $966M | $882M | $386M | $162M | $167M | $173M | $171M | |
| Shares Outstanding | 416,214,102 | 411,584,851 | 408,824,093 | 408,824,093 | 396,598,008 | 392,538,081 | 360,103,901 | 325,850,013 | 271,022,011 | 269,363,696 | 183,403,263 | 174,590,372 |
التدفق النقدي 17
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | $23.0K | $62.0K | $138.0K | $166.0K | $198.0K | |
| Stock-based Comp | $14M | $18M | $16M | $26M | $37M | $46M | $31M | $19M | $14M | $14M | $14M | $9M | |
| Deferred Tax | · | · | · | · | · | · | · | · | $11M | $9M | $-4M | $-4M | |
| Amort. of Intangibles | $3M | $3M | $3M | $3M | $2M | $1M | $679.0K | $646.0K | $646.0K | $645.0K | $646.0K | $646.0K | |
| Restructuring | $36M | $0 | $11M | $14M | $14M | · | · | · | · | · | · | · | |
| Operating Cash Flow | $7M | $-31M | $7M | $-180M | $-67M | $-22M | $-9M | $-95M | $-33M | $-72M | $-84M | $-75M | |
| CapEx | · | · | · | · | · | $252.0K | $2M | $58.0K | $12.0K | $21.0K | $28.0K | · | |
| Investing Cash Flow | $9M | $-46M | $-26M | $175M | $104M | $-377M | $-2M | $-58.0K | $-12.0K | $-21.0K | · | · | |
| Net Debt Issued | · | · | · | · | · | $-50M | · | $-15M | $-3M | · | · | · | |
| Stock Issued | · | · | · | · | · | · | $440M | $265M | · | $65M | · | · | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | $194.0K | · | |
| Net Stock Activity | · | · | · | · | · | · | · | $265M | · | $65M | $-194.0K | · | |
| Financing Cash Flow | $-2M | $-1M | $230.0K | $-379.0K | $-5M | $-59M | $410M | $271M | $8M | $63M | · | · | |
| Net Change in Cash | $14M | $-78M | $-18M | $-5M | $32M | $-458M | $398M | $176M | $-25M | $-9M | $-13M | $-72M | |
| Taxes Paid | $1M | $4M | $2M | $-2M | $4M | $-207.0K | $-67.0K | · | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | $-22M | · | $-95M | $-33M | $-72M | $-85M | · | |
| Levered FCF | · | · | · | · | · | $-25M | · | $-104M | $-45M | $-93M | $-104M | · |
الربحية 8
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 56.6% | 35.6% | 53.9% | · | · | 78.6% | · | 76.2% | 75.2% | 73.6% | 65.9% | 62.2% | |
| Operating Margin | -23.5% | -40.2% | -22.0% | · | · | -3.2% | · | -47.2% | -25.1% | -50.4% | -120.1% | -177.0% | |
| Net Margin | -18.2% | -35.9% | -19.3% | · | · | -2.9% | · | -50.8% | -37.5% | -66.4% | -140.9% | -104.0% | |
| Pretax Margin | -16.9% | -33.8% | -17.5% | · | · | -2.8% | · | -50.8% | -30.3% | -58.7% | -144.7% | -109.2% | |
| EBITDA Margin | -23.5% | -40.2% | -22.0% | · | · | -3.2% | · | -47.2% | -25.1% | -50.4% | -120.1% | -177.0% | |
| ROA | -5.7% | -10.8% | -6.9% | · | · | -1.9% | · | -42.5% | -41.3% | -50.8% | -66.9% | -26.6% | |
| ROE | -8.4% | -16.2% | -10.7% | · | · | -2.9% | · | -234.1% | 183.0% | 124.9% | 105.9% | 92.2% | |
| ROIC | -11.8% | -20.1% | -13.5% | · | · | -3.3% | · | -46.6% | -200.8% | -80.6% | 417.0% | -551.6% |
السيولة والملاءة 5
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | 3.3 | 2.8 | · | · | 2.9 | · | 2.4 | 1.4 | 1.9 | 2.8 | 3.6 | |
| Quick Ratio | 2.2 | 2.3 | 1.8 | · | · | 2.1 | · | 2.0 | 1.1 | 1.6 | 2.4 | 3.2 | |
| Debt / Equity | · | · | · | · | · | 0.0 | · | 0.5 | -1.4 | -11.2 | -0.8 | -1.2 | |
| LT Debt / Equity | · | · | · | · | · | · | · | 0.3 | -1.1 | -9.4 | -0.7 | -1.0 | |
| Interest Coverage | -7167.1 | -13113.9 | -8448.5 | · | · | -7.5 | · | -12.2 | -4.7 | -3.5 | -4.9 | -5.2 |
الكفاءة 3
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | 0.4 | · | · | 0.7 | · | 0.8 | 1.1 | 0.8 | 0.5 | 0.3 | |
| Inventory Turnover | · | · | · | · | · | 1.0 | · | 1.2 | 1.8 | 1.7 | 1.7 | 1.2 | |
| Receivables Turnover | 1.7 | 1.8 | 2.3 | · | · | 4.5 | · | 4.1 | 5.5 | 7.7 | 7.5 | 9.4 |
معدلات النمو 3
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -6.6% | -25.5% | -16.9% | -36.7% | -5.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -16.7% | -26.8% | -20.6% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -19.0% | · | · | · | · | · | · | · | · | · | · | · |
التقييم (آخر 12 شهرًا) 14
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $214M | $229M | $307M | $369M | $583M | $614M | $430M | $229M | $181M | $130M | $82M | $54M | |
| Net Income TTM | $-39M | $-82M | $-59M | $-106M | $8M | $-18M | $-23M | $-116M | $-68M | $-86M | $-115M | $-56M | |
| Market Cap | $5.81B | $4.03B | $7.11B | · | · | $38.39B | · | $88.70B | $21.74B | $16.59B | $6.93B | $3.42B | |
| Enterprise Value | · | · | · | · | · | $37.89B | · | $88.53B | $21.76B | $16.60B | $6.93B | $3.41B | |
| P/E | -155.1 | -49.0 | -116.0 | -93.1 | 3370.0 | -1956.0 | -6125.7 | -697.9 | -320.8 | -150.2 | -45.5 | -54.4 | |
| P/S | 27.2 | 17.6 | 23.2 | · | · | 62.5 | · | 387.0 | 120.0 | 127.6 | 84.8 | 63.1 | |
| P/B | 12.7 | 8.3 | 12.9 | · | · | 61.2 | · | 582.3 | -333.9 | -1831.8 | -53.7 | -38.7 | |
| P / Tangible Book | 13.0 | 8.6 | 13.4 | 17.1 | 41.5 | 62.6 | · | · | · | · | · | · | |
| P / Cash Flow | 863.6 | -130.0 | 1033.9 | · | · | -1765.4 | · | -936.6 | -661.9 | -231.0 | -81.8 | -47.3 | |
| P / FCF | · | · | · | · | · | -1745.2 | · | -936.0 | -661.7 | -231.0 | -81.8 | · | |
| EV / EBITDA | · | · | · | · | · | -1927.7 | · | -818.0 | -477.6 | -252.9 | -70.6 | -35.5 | |
| EV / FCF | · | · | · | · | · | -1722.4 | · | -934.2 | -662.3 | -231.0 | -81.8 | · | |
| EV / Revenue | · | · | · | · | · | 61.7 | · | 386.2 | 120.1 | 127.6 | 84.8 | 62.9 | |
| Earnings Yield | -0.64% | -2.0% | -0.86% | -1.1% | 0.03% | -0.05% | -0.02% | -0.14% | -0.31% | -0.67% | -2.2% | -1.8% |
قائمة الدخل 16
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $42M | $45M | $49M | $50M | $73M | $42M | $62M | $42M | $67M | $57M | $75M | $66M | $80M | $86M | $90M | $90M | |
| Gross Profit | $15M | $18M | $23M | $22M | $50M | $25M | $-10M | $16M | $43M | $32M | $45M | $30M | $43M | $48M | $64M | $63M | |
| R&D Expense | $5M | $5M | $5M | $4M | $5M | $5M | $6M | $5M | $5M | $6M | $6M | $5M | $6M | $6M | $5M | $6M | |
| SG&A Expense | $22M | $21M | $20M | $20M | $39M | $37M | $37M | $37M | $39M | $40M | $44M | $45M | $51M | $60M | $68M | $59M | |
| Operating Expenses | $27M | $29M | $29M | $33M | $66M | $42M | $43M | $41M | $43M | $45M | $50M | $51M | $67M | $65M | $73M | $68M | |
| Operating Income | $-12M | $-11M | $-6M | $-11M | $-16M | $-17M | $-53M | $-25M | $-524.0K | $-14M | $-5M | $-21M | $-24M | $-17M | $-10M | $-5M | |
| Interest Income | $3M | $2M | · | · | $3M | $3M | · | · | · | · | · | · | · | · | · | · | |
| Other Non-op | $1M | $188.0K | $3M | $205.0K | $-85.0K | $253.0K | $-754.0K | $265.0K | $145.0K | $2M | $-1M | $-575.0K | $3M | $624.0K | $1M | $511.0K | |
| Pretax Income | $-8M | $-9M | $-853.0K | $-8M | $-13M | $-14M | $-50M | $-22M | $3M | $-9M | $-2M | $-19M | $-18M | $-14M | $-7M | $-4M | |
| Income Tax | $-219.0K | $2M | $371.0K | $-377.0K | $689.0K | $2M | $-1M | $4M | $1M | $1M | $3M | $501.0K | $-355.0K | $2M | $-8M | $1M | |
| Net Income | $-8M | $-11M | $-1M | $-8M | $-14M | $-16M | $-49M | $-25M | $2M | $-10M | $-6M | $-19M | $-18M | $-16M | $856.0K | $-5M | |
| EPS (Basic) | $-0.02 | $-0.03 | $0.00 | $-0.02 | $-0.03 | $-0.04 | $-0.12 | $-0.06 | $0.00 | $-0.02 | $-0.02 | $-0.05 | $-0.04 | $-0.04 | $0.01 | $-0.01 | |
| EPS (Diluted) | $-0.02 | $-0.03 | $0.00 | $-0.02 | $-0.03 | $-0.04 | $-0.12 | $-0.06 | $0.00 | $-0.02 | $-0.02 | $-0.05 | $-0.04 | $-0.04 | $0.01 | $-0.01 | |
| Shares (Basic) | 416,444,000 | 419,054,000 | -828,446,000 | 415,531,000 | 414,477,000 | 413,422,000 | -821,210,000 | 411,150,000 | 410,851,000 | 410,146,000 | -814,787,000 | 408,417,000 | 407,848,000 | 406,177,000 | -799,451,000 | 404,614,000 | |
| Shares (Diluted) | 416,444,000 | 419,054,000 | -828,446,000 | 415,531,000 | 414,477,000 | 413,422,000 | -821,754,000 | 411,150,000 | 411,395,000 | 410,146,000 | -814,787,000 | 408,417,000 | 407,848,000 | 406,177,000 | -799,451,000 | 404,614,000 | |
| EBITDA | $-12M | $-11M | · | $-11M | $-16M | $-17M | · | $-25M | $-524.0K | $-14M | · | $-21M | $-24M | $-17M | · | $-5M |
الميزانية العمومية 24
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $144M | $131M | $135M | $123M | $148M | $120M | $121M | $157M | $216M | $214M | · | $271M | $233M | $191M | · | $240M | |
| Short-term Investments | $171M | $177M | $168M | $164M | $151M | $162M | $173M | $149M | $91M | $94M | · | $50M | $80M | $113M | · | $63M | |
| Receivables | $93M | $108M | $127M | $127M | $119M | $107M | $122M | $113M | $124M | $116M | · | $122M | $123M | $133M | · | $123M | |
| Inventory | $164M | $184M | $196M | $185M | $171M | $159M | $166M | $224M | $239M | $255M | · | $254M | $227M | $226M | · | $228M | |
| Prepaid Expense | $31M | $26M | $24M | $29M | $17M | $25M | $13M | $7M | $32M | $8M | · | $19M | $43M | $20M | · | $28M | |
| Current Assets | $603M | $626M | $650M | $628M | $607M | $573M | $595M | $650M | $702M | $688M | · | $718M | $706M | $684M | · | $687M | |
| PP&E (Net) | · | · | $12.0K | $13.0K | $14.0K | $15.0K | $16.0K | $24.0K | $49.0K | $81.0K | · | $147.0K | $179.0K | $187.0K | · | $999.0K | |
| PP&E (Gross) | · | · | $1M | · | · | · | $1M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $1M | · | · | · | $1M | · | · | · | · | · | · | · | · | · | |
| Intangibles | $12M | $13M | $13M | $14M | $15M | $16M | $16M | $17M | $18M | $19M | · | $20M | $20M | $21M | · | $22M | |
| Other Non-current Assets | $4M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | · | $1M | $2M | $2M | · | $456.0K | |
| Total Assets | $624M | $646M | $671M | $660M | $670M | $656M | $685M | $751M | $800M | $790M | · | $839M | $860M | $860M | · | $908M | |
| Accounts Payable | $19M | $48M | $45M | $37M | $45M | $46M | $40M | $41M | $54M | $68M | · | $53M | $54M | $59M | · | $93M | |
| Current Liabilities | $164M | $180M | $194M | $182M | $186M | $162M | $180M | $202M | $231M | $224M | · | $267M | $271M | $244M | · | $287M | |
| Capital Leases | $5M | $6M | $6M | $7M | $7M | $8M | $8M | $8M | $8M | $8M | · | $9M | $9M | $10M | · | $10M | |
| Other Non-current Liabilities | $11M | $11M | $11M | $12M | $12M | $12M | $12M | $9M | $9M | $9M | · | $7M | $7M | $9M | · | $10M | |
| Total Liabilities | $181M | $196M | $211M | $201M | $205M | $182M | $199M | $219M | $248M | $244M | · | $286M | $291M | $275M | · | $320M | |
| Common Stock | $315M | $314M | $310M | $310M | $309M | $308M | $305M | $305M | $305M | $305M | · | $302M | $302M | $301M | · | $299M | |
| Paid-in Capital | $1.92B | $1.92B | $1.92B | $1.92B | $1.92B | $1.92B | $1.91B | $1.91B | $1.91B | $1.90B | · | $1.90B | $1.89B | $1.89B | · | $1.88B | |
| Retained Earnings | $-1.73B | $-1.72B | $-1.71B | $-1.71B | $-1.70B | $-1.68B | $-1.67B | $-1.62B | $-1.59B | $-1.60B | · | $-1.58B | $-1.56B | $-1.54B | · | $-1.53B | |
| Treasury Stock | $69M | $69M | $67M | $67M | $67M | $66M | $65M | $65M | $65M | $65M | · | $64M | $63M | $63M | · | $62M | |
| Stockholders' Equity | $444M | $449M | $459M | $459M | $465M | $474M | $486M | $531M | $552M | $546M | $552M | $553M | $569M | $585M | $595M | $588M | |
| Liabilities + Equity | $624M | $646M | $671M | $660M | $670M | $656M | $685M | $751M | $800M | $790M | · | $839M | $860M | $860M | · | $908M | |
| Shares Outstanding | 420,044,022 | 419,594,602 | 416,214,102 | 415,965,977 | 415,401,497 | 414,365,189 | 411,584,851 | 411,261,678 | 411,113,770 | 410,735,780 | · | 408,551,020 | 408,133,807 | 407,265,944 | 408,824,093 | 403,828,955 |
التدفق النقدي 9
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $2M | $2M | $2M | $6M | $4M | $3M | $5M | $4M | $5M | $5M | $4M | $2M | $6M | $7M | $5M | |
| Amort. of Intangibles | $636.0K | $637.0K | $701.0K | $866.0K | $728.0K | $729.0K | $729.0K | $728.0K | $729.0K | $729.0K | $701.0K | $701.0K | $701.0K | $702.0K | $636.0K | $636.0K | |
| Restructuring | $40.0K | $3M | $4M | $9M | $23M | · | · | · | · | · | $229.0K | $711.0K | $10M | · | $-180.0K | $3M | |
| Operating Cash Flow | $7M | $6M | $15M | $-13M | $17M | $-12M | $-13M | $-2M | $-3M | $-13M | $-645.0K | $7M | $7M | $-7M | $2M | $-18M | |
| Investing Cash Flow | $6M | $-8M | $-4M | $-12M | $12M | $12M | $-23M | $-57M | $5M | $29M | $-71M | $31M | $34M | $-20M | $-28M | $31M | |
| Stock Issued | · | · | · | · | · | · | · | $0 | · | · | · | $0 | · | · | · | $0 | |
| Financing Cash Flow | $-247.0K | $-2M | $-4.0K | $-248.0K | $-663.0K | $-1M | $17.0K | $-68.0K | $34.0K | $-1M | $83.0K | $-277.0K | $60.0K | $364.0K | $38.0K | $-156.0K | |
| Net Change in Cash | $12M | $-4M | $12M | $-25M | $28M | $-2M | $-36M | $-59M | $2M | $15M | $-72M | $38M | $42M | $-26M | $-26M | $12M | |
| Taxes Paid | $1M | $2M | $1M | $-1.0K | $-169.0K | $22.0K | $6M | $-1M | $-698.0K | $29.0K | $3M | $-432.0K | $-633.0K | $38.0K | $-292.0K | $622.0K |
الربحية 8
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 35.5% | 39.4% | · | 44.7% | 69.2% | 59.8% | · | 38.5% | 63.4% | 56.5% | · | 45.1% | 53.2% | 55.8% | · | 69.9% | |
| Operating Margin | -28.4% | -25.1% | · | -22.4% | -22.0% | -39.9% | · | -59.5% | -0.78% | -24.0% | · | -32.5% | -29.9% | -20.2% | · | -5.7% | |
| Net Margin | -18.1% | -23.3% | · | -15.6% | -19.4% | -37.4% | · | -59.4% | 2.3% | -17.6% | · | -29.2% | -21.9% | -19.1% | · | -5.7% | |
| Pretax Margin | -18.6% | -19.3% | · | -16.3% | -18.5% | -32.4% | · | -50.9% | 4.3% | -15.3% | · | -28.5% | -22.4% | -16.9% | · | -4.3% | |
| EBITDA Margin | -28.4% | -25.1% | · | -22.4% | -22.0% | -39.9% | · | -59.5% | -0.78% | -24.0% | · | -32.5% | -29.9% | -20.2% | · | -5.7% | |
| ROA | -1.2% | -1.6% | · | -1.1% | -1.9% | -2.2% | · | -3.2% | 0.18% | -1.2% | · | -2.2% | -1.9% | -1.8% | · | -0.53% | |
| ROE | -1.7% | -2.3% | · | -1.6% | -2.8% | -3.1% | · | -4.6% | 0.27% | -1.8% | · | -3.4% | -3.1% | -2.7% | · | -0.84% | |
| ROIC | -2.6% | -3.0% | · | -2.3% | -3.6% | -4.1% | · | -5.5% | -0.05% | -2.9% | · | -4.0% | -4.1% | -3.4% | · | -1.2% |
السيولة والملاءة 2
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.7 | 3.5 | · | 3.4 | 3.3 | 3.5 | · | 3.2 | 3.0 | 3.1 | · | 2.7 | 2.6 | 2.8 | · | 2.4 | |
| Quick Ratio | 2.5 | 2.3 | · | 2.3 | 2.2 | 2.4 | · | 2.1 | 1.9 | 1.9 | · | 1.7 | 1.6 | 1.8 | · | 1.5 |
الكفاءة 2
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 0.4 | 0.4 | · | 0.4 | 0.6 | 0.4 | · | 0.4 | 0.5 | 0.5 | · | 0.5 | 0.6 | 0.7 | · | 0.7 |
التقييم (آخر 12 شهرًا) 9
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $210M | $210M | · | $207M | $225M | $208M | · | $232M | $270M | $289M | · | $322M | $350M | $365M | · | $421M | |
| Net Income TTM | $-40M | $-48M | · | $-63M | $-53M | $-49M | · | $-53M | $-45M | $-63M | · | $-58M | $-109M | $-123M | · | $-120M | |
| Market Cap | $6.70B | $6.07B | · | $6.81B | $6.74B | $3.73B | · | $5.18B | $5.67B | $7.31B | · | $7.52B | $9.71B | $12.22B | · | $8.80B | |
| P/E | -159.4 | -120.5 | · | -109.2 | -124.8 | -75.0 | · | -96.9 | -125.5 | -118.7 | · | -131.4 | -88.1 | -96.8 | · | -72.7 | |
| P/S | 31.9 | 29.0 | · | 33.0 | 30.0 | 17.9 | · | 22.3 | 21.0 | 25.3 | · | 23.3 | 27.7 | 33.5 | · | 20.9 | |
| P/B | 15.1 | 13.5 | · | 14.8 | 14.5 | 7.9 | · | 9.8 | 10.3 | 13.4 | · | 13.6 | 17.1 | 20.9 | · | 15.0 | |
| P / Tangible Book | 15.5 | 13.9 | · | 15.3 | 15.0 | 8.1 | · | 10.1 | 10.6 | 13.9 | · | 14.1 | 17.7 | 21.7 | · | 15.5 | |
| P / Cash Flow | · | 949.8 | · | · | · | -299.3 | · | · | · | -580.2 | · | · | · | -1743.4 | · | · | |
| Earnings Yield | -0.63% | -0.83% | · | -0.92% | -0.80% | -1.3% | · | -1.0% | -0.80% | -0.84% | · | -0.76% | -1.1% | -1.0% | · | -1.4% |
القوائم المالية قائمة الدخل، الميزانية العمومية، التدفقات النقدية — سنويًا، آخر 5 سنوات
قائمة الدخل
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| الإيرادات | $214M | $229M | $307M | $369M | $583M |
| هامش الربح الإجمالي % | 56.6% | 35.6% | 53.9% | — | — |
| هامش الربح التشغيلي % | -23.5% | -40.2% | -22.0% | — | — |
| صافي الدخل | $-39M | $-82M | $-59M | $-106M | $8M |
| EPS المخفف | $-0.09 | $-0.20 | $-0.15 | $-0.26 | $0.02 |
الميزانية العمومية
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| النسبة الحالية | 3.3 | 3.3 | 2.8 | — | — |
| النسبة السريعة | 2.2 | 2.3 | 1.8 | — | — |
مقاييسي قائمة المراقبة الشخصية الخاصة بك — صفوف مختارة من الأساسيات الكاملة
📊
اختر المقاييس التي تهمك — انقر فوق علامة ➕ بجوار أي صف في الأساسيات الكاملة أعلاه.
يتم حفظ اختيارك ويتبعك عبر جميع الأسهم.
الملاك المؤسسيون (13F) 90 مقدمي إقرار · $59.1M إجمالي · حتى تاريخ 30 يونيو، 2026
المؤسسات التي تبلغ عن حيازتها لهذا السهم في نموذج SEC 13F ربع السنوي الخاص بها. المراكز الطويلة فقط؛ قد يظهر مقدم واحد مرتين لأرجل خيارات منفصلة. الأرجل الكبيرة المتعاكسة من خيارات البيع/الشراء تعكس عادةً صناعة السوق أو المخزون المتحوط، وليس القناعة الاتجاهية.
النشاط المؤسسي — Q2 2026 مقابل الربع السابق
| مراكز جديدة | المراكز الخارجة | زيادة | انخفض | صافي التغير في الأسهم |
|---|---|---|---|---|
| 23 (+15 مقابل الربع السابق) | 7 (-12 مقابل الربع السابق) | 19 (+1 مقابل الربع السابق) | 10 (-3 مقابل الربع السابق) | +89K |
مقارنة بـ Q1 2026. المواعيد النهائية لتقديم إقرارات نموذج 13F لهيئة الأوراق المالية والبورصات (SEC) هي في غضون 45 يومًا من نهاية الربع بالإضافة إلى فترة سماح قصيرة للمقدمين المتأخرين — يتم تخطي الأرباع التي لا تزال ضمن هذه النافذة لصالح أحدث زوج تم الإبلاغ عنه بالكامل.
| مؤسسة | القيمة | الأسهم | % من 13F المتتبعة | النوع |
|---|---|---|---|---|
| Sarissa Capital Management LP | $26673916 | 1673395 | 45,11% | الأسهم |
| Kynam Capital Management, LP | $8495733 | 532982 | 14,37% | الأسهم |
| Waterfront Wealth Inc. | $3183561 | 213949 | 5,38% | الأسهم |
| Brooklands Fund Management Ltd | $2741449 | 177325 | 4,64% | الأسهم |
| Eversept Partners, LP | $2316018 | 145296 | 3,92% | الأسهم |
| MILLENNIUM MANAGEMENT LLC | $1845980 | 115808 | 3,12% | الأسهم |
| TWO SIGMA INVESTMENTS, LP | $1602145 | 100511 | 2,71% | الأسهم |
| BNP PARIBAS FINANCIAL MARKETS | $1144699 | 71813 | 1,94% | الأسهم |
| CITADEL ADVISORS LLC | $971671 | 60958 | 1,64% | الأسهم |
| LCM Capital Management Inc | $818710 | 51362 | 1,38% | الأسهم |
| RENAISSANCE TECHNOLOGIES LLC | $771002 | 48369 | 1,30% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $765120 | 48000 | 1,29% | عقد خيار الشراء |
| George Kaiser Family Foundation | $593080 | 37207 | 1,00% | الأسهم |
| JANE STREET GROUP, LLC | $523294 | 32829 | 0,89% | الأسهم |
| TWO SIGMA ADVISERS, LP | $516265 | 36995 | 0,87% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $462276 | 29001 | 0,78% | الأسهم |
| STATE STREET CORP | $398755 | 25016 | 0,67% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $385748 | 24200 | 0,65% | عقد خيار البيع |
| Bleakley Financial Group, LLC | $374670 | 23505 | 0,63% | الأسهم |
| State of New Jersey Common Pension Fund D | $300931 | 18879 | 0,51% | الأسهم |
| CITADEL ADVISORS LLC | $299672 | 18800 | 0,51% | عقد خيار البيع |
| COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS | $292818 | 18370 | 0,50% | الأسهم |
| R Squared Ltd | $269992 | 16938 | 0,46% | الأسهم |
| State of Tennessee, Department of Treasury | $239164 | 15004 | 0,40% | الأسهم |
| MORGAN STANLEY | $237618 | 14907 | 0,40% | الأسهم |
| Quadrature Capital Ltd | $236581 | 14842 | 0,40% | الأسهم |
| Quinn Opportunity Partners LLC | $228022 | 14305 | 0,39% | الأسهم |
| Cubist Systematic Strategies, LLC | $224390 | 13699 | 0,38% | الأسهم |
| EntryPoint Capital, LLC | $194882 | 12226 | 0,33% | الأسهم |
| Jump Financial, LLC | $191407 | 12008 | 0,32% | الأسهم |
| GEODE CAPITAL MANAGEMENT, LLC | $187629 | 11771 | 0,32% | الأسهم |
| WELLS FARGO & COMPANY/MN | $179564 | 11265 | 0,30% | الأسهم |
| NJ State Employees Deferred Compensation Plan | $178542 | 10900 | 0,30% | الأسهم |
| Verdad Advisers, LP | $166270 | 10431 | 0,28% | الأسهم |
| CITADEL ADVISORS LLC | $164182 | 10300 | 0,28% | عقد خيار الشراء |
| Steward Partners Investment Advisory, LLC | $142025 | 8910 | 0,24% | الأسهم |
| NEW YORK STATE COMMON RETIREMENT FUND | $121224 | 7605 | 0,21% | الأسهم |
| OSAIC HOLDINGS, INC. | $104537 | 6559 | 0,18% | الأسهم |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | $92038 | 5774 | 0,16% | الأسهم |
| MERCER GLOBAL ADVISORS INC /ADV | $80099 | 5025 | 0,14% | الأسهم |
| UBS Group AG | $67171 | 4214 | 0,11% | الأسهم |
| RHUMBLINE ADVISERS | $59498 | 3733 | 0,10% | الأسهم |
| NATIONAL BANK OF CANADA /FI/ | $40137 | 2518 | 0,07% | الأسهم |
| AMERIPRISE FINANCIAL INC | $30318 | 1902 | 0,05% | الأسهم |
| ROYAL BANK OF CANADA | $28000 | 1787 | 0,05% | الأسهم |
| GAMMA Investing LLC | $25121 | 1576 | 0,04% | الأسهم |
| RAYMOND JAMES FINANCIAL INC | $22332 | 1401 | 0,04% | الأسهم |
| NewEdge Advisors, LLC | $21471 | 1347 | 0,04% | الأسهم |
| Farther Finance Advisors, LLC | $15271 | 958 | 0,03% | الأسهم |
| BlackRock, Inc. | $13677 | 858 | 0,02% | الأسهم |
| IFP Advisors, Inc | $12975 | 814 | 0,02% | الأسهم |
| Beaird Harris Wealth Management, LLC | $11955 | 750 | 0,02% | الأسهم |
| ACADIAN ASSET MANAGEMENT LLC | $11467 | 720984 | 0,02% | الأسهم |
| CoreCap Advisors, LLC | $8528 | 535 | 0,01% | الأسهم |
| Integrated Wealth Concepts LLC | $8449 | 530 | 0,01% | الأسهم |
| JONES FINANCIAL COMPANIES LLLP | $7844 | 493 | 0,01% | الأسهم |
| BARCLAYS PLC | $4862 | 305 | 0,01% | الأسهم |
| JPMORGAN CHASE & CO | $3853 | 242 | 0,01% | الأسهم |
| CWM, LLC | $3644 | 252 | 0,01% | الأسهم |
| Westside Investment Management, Inc. | $3268 | 205 | 0,01% | الأسهم |
| Global Retirement Partners, LLC | $2646 | 166 | 0,00% | الأسهم |
| GROUP ONE TRADING LLC | $2072 | 130 | 0,00% | الأسهم |
| HARBOUR INVESTMENTS, INC. | $1562 | 98 | 0,00% | الأسهم |
| Federation des caisses Desjardins du Quebec | $1435 | 90 | 0,00% | الأسهم |
| Activest Wealth Management | $797 | 50 | 0,00% | الأسهم |
| HighMark Wealth Management LLC | $797 | 50 | 0,00% | الأسهم |
| Arax Advisory Partners | $685 | 43 | 0,00% | الأسهم |
| Darwin Wealth Management, LLC | $398 | 25 | 0,00% | الأسهم |
| Continuum Advisory, LLC | $303 | 19 | 0,00% | الأسهم |
| Caitong International Asset Management Co., Ltd | $271 | 17 | 0,00% | الأسهم |
| SEI INVESTMENTS CO | $260 | 16 | 0,00% | الأسهم |
| Hayek Kallen Investment Management | $204 | 12809 | 0,00% | الأسهم |
| Atlantic Union Bankshares Corp | $192 | 12 | 0,00% | الأسهم |
| Truvestments Capital LLC | $191 | 12 | 0,00% | الأسهم |
| Parallel Advisors, LLC | $159 | 10 | 0,00% | الأسهم |
| Creative Capital Management Investments LLC | $143 | 9 | 0,00% | الأسهم |
| Key Financial Inc | $128 | 8 | 0,00% | الأسهم |
| CITIGROUP INC | $128 | 8 | 0,00% | الأسهم |
| MCGUIRE CAPITAL ADVISORS INC | $112 | 7 | 0,00% | الأسهم |
| EASTERN BANK | $112 | 7 | 0,00% | الأسهم |
| Lindbrook Capital, LLC | $90 | 200 | 0,00% | الأسهم |
| Oakmont Advisory Group, LLC | $80 | 5 | 0,00% | الأسهم |
| Allworth Financial LP | $80 | 5 | 0,00% | الأسهم |
| Crewe Advisors LLC | $80 | 5 | 0,00% | الأسهم |
| BFSG, LLC | $80 | 5 | 0,00% | الأسهم |
| SBI Securities Co., Ltd. | $80 | 5 | 0,00% | الأسهم |
| WHITTIER TRUST CO | $63 | 4 | 0,00% | الأسهم |
| Caitlin John, LLC | $32 | 2 | 0,00% | الأسهم |
| WHITTIER TRUST CO OF NEVADA INC | $15 | 1 | 0,00% | الأسهم |
| JFS WEALTH ADVISORS, LLC | $15 | 1 | 0,00% | الأسهم |
المطلعون على الشركة 37 من المطلعين · مسؤولون 17 · مديرون 22
| مطلع | الدور | آخر نشاط | الأسهم المملوكة | مشتريات 12 شهرًا | مبيعات 12 شهرًا | صافي 12 شهرًا |
|---|---|---|---|---|---|---|
| Aaron Berg | President and CEO | 26 يونيو، 2026 M | 85648 | 0 | 0 | $0 |
| Patrick Holt | President and CEO | 22 يناير، 2024 P | 314426 | 0 | 0 | $0 |
| Karim Mikhail | President and CEO | 21 فبراير، 2023 A | 283507 | 0 | 0 | $0 |
| John F Thero | President and CEO | 19 نوفمبر، 2019 S | 2342285 | 0 | 0 | $0 |
| Peter L. Fishman | SVP, CFO | 1 أغسطس، 2026 A | 7619 | 0 | 0 | $0 |
| Thomas Charles Reilly | EVP and CFO | 1 يوليو، 2024 M | 94305 | 0 | 0 | $0 |
| Michael Wayne Kalb | SVP and CFO | 16 ديسمبر، 2019 M | 21552 | 0 | 0 | $0 |
| David Paul Keenan | EVP, Chief Operating Officer | 1 يوليو، 2026 A | 13470 | 0 | 0 | $0 |
| Jonathan Provoost | EVP, Chief Legal Officer | 1 يوليو، 2026 A | 4624 | 0 | 0 | $0 |
| Steven B Ketchum | EVP, Chief Scientific Officer | 1 يوليو، 2026 A | 42680 | 0 | 0 | $0 |
| Joseph T Kennedy | General Counsel | 7 أكتوبر، 2019 F | 125723 | 0 | 0 | $0 |
| Mark Salyer | Chief Commercial Officer | 1 فبراير، 2018 A | — | 0 | 0 | $0 |
| Michael James Farrell | VP, Finance | 1 فبراير، 2016 A | 30190 | 0 | 0 | $0 |
| Paul Huff | Chief Commercial Officer | 26 يوليو، 2012 A | 0 | 0 | 0 | $0 |
| Stuart D Sedlack | Senior Vice President | 26 يوليو، 2012 A | 0 | 0 | 0 | $0 |
| Paresh Soni | SVP and Head of Development | 1 فبراير، 2012 A | 0 | 0 | 0 | $0 |
| Frederick W Ahlholm | Vice President Finance | 1 فبراير، 2012 A | 0 | 0 | 0 | $0 |
| Oliver O'Connor | مدير | 18 إبريل، 2026 M | 801 | 0 | 0 | $0 |
| Paul Cohen | مدير | 18 إبريل، 2026 M | 836 | 0 | 0 | $0 |
| Diane E. Sullivan | مدير | 18 إبريل، 2026 M | 836 | 0 | 0 | $0 |
| Louis Sterling III | مدير | 18 إبريل، 2026 M | 4049 | 0 | 0 | $0 |
| Patrice Eadon Bonfiglio | مدير | 18 إبريل، 2026 M | 836 | 0 | 0 | $0 |
| Keith Horn | مدير | 18 إبريل، 2026 M | 836 | 0 | 0 | $0 |
| Odysseas D Kostas | مدير | 18 إبريل، 2026 M | 836 | 0 | 0 | $0 |
| Mark Dipaolo | مدير | 18 إبريل، 2025 M | 401 | 0 | 0 | $0 |
| Olsen Per Wold | مدير | 10 يناير، 2023 M | 171027 | 0 | 0 | $0 |
| David M Stack | مدير | 4 يونيو، 2021 P | 40000 | 0 | 0 | $0 |
| Joseph S Zakrzewski | مدير | 3 يناير، 2020 M | 84547 | 0 | 0 | $0 |
| Lars Ekman | مدير | 12 نوفمبر، 2019 M | 0 | 0 | 0 | $0 |
| Kristine Peterson | مدير | 20 مايو، 2019 A | 0 | 0 | 0 | $0 |
| Patrick J O'Sullivan | مدير | 20 مايو، 2019 A | — | 0 | 0 | $0 |
| VAN HEEK G JAN | مدير | 20 مايو، 2019 A | 14168 | 0 | 0 | $0 |
| Dr. James I. Healy | مدير | 11 يوليو، 2016 A | 90000 | 0 | 0 | $0 |
| GORDON CARL L | مدير | 4 سبتمبر، 2012 S | 5700 | 0 | 0 | $0 |
| Joseph Anderson | مدير | 10 يوليو، 2012 A | 11683 | 0 | 0 | $0 |
| David W Feigal Jr | مدير | 12 يوليو، 2011 A | — | 0 | 0 | $0 |
| Abingworth LLP | مالك 10% | 19 إبريل، 2012 S | 1599168 | 0 | 0 | $0 |
المطلعون من إيداعات SEC Form 3/4/5؛ صافي = سوق مفتوح فقط
الناشطون والمالكون بنسبة 5%+ 34 حيازة
المستثمرون الذين قدموا الجدول الزمني 13D لدى هيئة الأوراق المالية والبورصات — ملكية مستفيدة تزيد عن 5% مع نية التأثير على المُصدر (حصص الناشطين، حملات مجلس الإدارة، الاندماج والاستحواذ). يعرض كل صف أحدث حالة معروفة لمركز مقدم الطلب هذا.
| مقدم | مقدم | حصة | الحالة | الغرض | إيداع |
|---|---|---|---|---|---|
| Sarissa Capital Management LP, Alexander J Denner ×3 إيداعات | 25 مارس، 2025 | 8,08% | تعديل | حملة مجلس الإدارة | SEC |
| 28 فبراير، 2023 | — | إيداع أولي | — | SEC | |
| 27 فبراير، 2023 | — | إيداع أولي | — | SEC | |
| 21 فبراير، 2023 | — | إيداع أولي | — | SEC | |
| OR ×6 إيداعات | 15 فبراير، 2023 | — | إيداع أولي | — | SEC |
| 14 فبراير، 2023 | — | إيداع أولي | — | SEC | |
| 10 فبراير، 2023 | — | إيداع أولي | — | SEC | |
| 19 يناير، 2023 | — | إيداع أولي | — | SEC | |
| 16 يونيو، 2022 | — | إيداع أولي | — | SEC | |
| Sofinnova Venture Partners VII, L.P. (“SVP VII”), Sofinnova Management VII, L.L.C. (“SM VII”), Dr. Michael F. Powell (“Powell”), Dr. James I. Healy (“Healy”), Eric P. Buatois (“Buatois”) ×4 إيداعات | 23 أغسطس، 2013 | — | إيداع أولي | — | SEC |
| Abingworth LLP 98-051-8585, Abingworth Bioventures V Co-Invest Growth Equity Fund LP 98-057-9772, Abingworth Bioventures V L.P. 98-051-8587, Abingworth Bioequities Master Fund Limited 66-066-0960 ×10 إيداعات | 22 يوليو، 2013 | — | إيداع أولي | حملة مجلس الإدارة | SEC |
| Boxer Capital, LLC, Boxer Asset Management Inc., Joseph Lewis ×4 إيداعات | 24 أغسطس، 2011 | — | إيداع أولي | — | SEC |
| OrbiMed Advisors LLC, OrbiMed Capital GP III LLC, Samuel D. Isaly ×14 إيداعات | 28 إبريل، 2011 | — | إيداع أولي | — | SEC |
| Fountain Healthcare Partners Fund 1, L.P. (“ Fountain ”), Fountain Healthcare Partners Ltd., Manus Rogan, Aidan King, Ena Prosser, Justin Lynch ×2 إيداعات | 10 ديسمبر، 2010 | — | إيداع أولي | — | SEC |
| Longitude Capital Partners, LLC (2), Longitude Venture Partners, L.P. (2), Longitude Capital Associates, L.P. (2), Patrick G. Enright (2), Juliet Tammenoms Bakker (2) | 26 أكتوبر، 2010 | — | إيداع أولي | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.